Mylan NV (MYL)

41.45
NASDAQ : Health Technology
Prev Close 41.28
Day Low/High 41.16 / 42.00
52 Wk Low/High 29.39 / 47.82
Avg Volume 5.90M
Exchange NASDAQ
Shares Outstanding 536.28M
Market Cap 22.10B
EPS 0.90
P/E Ratio 24.87
Div & Yield N.A. (N.A)

Latest News

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

The Swiss pharmaceutical firm's U.S. generic pill business could attract as much as $1.6 billion, Reuters reported.

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report

A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOCC, FET, IMMU, INVA, KMDA, SPH Downgrades: COR, EARN, EML, ENS, MSON, MYL, NCR, OFC, PBH, PCYO, THR, UBA, UBNT, UFS, WHG Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Mylan Becomes #238 Most Shorted S&P 500 Component, Replacing Colgate-Palmolive

Mylan Becomes #238 Most Shorted S&P 500 Component, Replacing Colgate-Palmolive

The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Mylan Expands Access To HIV/AIDS Medicines With Launch Of First Generic Sustiva® Tablets

Mylan Expands Access To HIV/AIDS Medicines With Launch Of First Generic Sustiva® Tablets

- Launch further strengthens Mylan's leading antiretroviral portfolio -

Mylan And Biocon Receive Positive CHMP Opinion For Semglee™, Biosimilar Insulin Glargine

Mylan And Biocon Receive Positive CHMP Opinion For Semglee™, Biosimilar Insulin Glargine

First biosimilar from Mylan and Biocon's joint portfolio recommended for approval in the European Union (EU)

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Are Politics and Proxy Firms Killing Your Investment Returns?

Are Politics and Proxy Firms Killing Your Investment Returns?

Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.

Are Politics and Proxy Firms Hurting Your Investment Returns?

Stick to the fundamentals when making investment decisions.

Why Hospitals Shouldn't Terrify Generic Drug Companies

Why Hospitals Shouldn't Terrify Generic Drug Companies

A group of hospital systems led by Intermountain Healthcare said Jan. 18 they are planning to form a not-for-profit generic drug firm to address drug shortages and high costs.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: IIIN, MYL, NUAN, SKY Downgrades: ADTN, CODI, PLXS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Mylan To Complete $1 Billion Share Repurchase Plan

Mylan To Complete $1 Billion Share Repurchase Plan

Abbott sells remaining 20.3 million shares of Mylan

Blizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports

Blizzard Pounds New York, Boston as 'Bomb Cyclone' Cripples East Coast Airports

A 'Bomb Cyclone' snowstorm could dump as much as 18 inches on New York and Boston Thursday, the National Weather Service has warned, as the Atlantic coast faces yet another extreme weather battering.

Momenta And Mylan Announce Development Strategy For M710, A Proposed Biosimilar To EYLEA® (aflibercept)

Momenta And Mylan Announce Development Strategy For M710, A Proposed Biosimilar To EYLEA® (aflibercept)

-- Targeting the initiation of a pivotal patient clinical trial in the first half of 2018 --

Mylan Adds To U.S. Women's Healthcare Portfolio With FDA Approval Of First Generic For Estrace® Cream

Mylan Adds To U.S. Women's Healthcare Portfolio With FDA Approval Of First Generic For Estrace® Cream

Mylan now offers estradiol in four delivery methods

Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related To Teva's Cold Filtration Patents For Copaxone® 40 Mg/mL

Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related To Teva's Cold Filtration Patents For Copaxone® 40 Mg/mL

Teva also agrees to withdraw Irish equivalent to U.S. patents from litigation in Ireland

3 Things You Must Know About Wall Street as You Head to Lunch

3 Things You Must Know About Wall Street as You Head to Lunch

The Dow Jones Industrial Average soars on Monday, and the S&P 500 posts a sharp increase as the Senate passes its version of U.S. tax reform.

TheStreet Quant Rating: C+ (Hold)